# OnCo record idea-bispecific-vs-car-t-second-line (idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/ideas/idea-bispecific-vs-car-t-second-line/>
  a schema:CreativeWork ;
  onco:kind "idea" ;
  schema:identifier "idea-bispecific-vs-car-t-second-line" ;
  schema:name "Head-to-head bispecific vs CAR-T in second-line LBCL"@en ;
  schema:description "Nobody has directly compared an off-the-shelf bispecific with CAR-T in the same patients; a trial would settle where each belongs."@en ;
  schema:url <https://onco.cc/ideas/idea-bispecific-vs-car-t-second-line/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:citation <https://doi.org/10.1056/NEJMoa2116133>, <https://doi.org/10.1056/NEJMoa1707447> ;
  onco:cancers <https://onco.cc/cancers/dlbcl/> ;
  onco:technologies <https://onco.cc/technologies/t-cell-engager/>, <https://onco.cc/technologies/car-t/> ;
  onco:drugs <https://onco.cc/drugs/epcoritamab/>, <https://onco.cc/drugs/glofitamab/>, <https://onco.cc/drugs/axicabtagene-ciloleucel/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-zuma-1-axi-cel-nejm-2017/>, <https://onco.cc/key-papers/paper-glofitamab-dlbcl-n-engl-j-med-2022/>, <https://onco.cc/key-papers/paper-glofitamab-dlbcl-lancet-2024/> .